BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18181723)

  • 1. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs.
    Hoffman FA; Heimbach JT; Sanders ME; Hibberd PL
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S53-7. PubMed ID: 18181723
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
    Mattia A; Merker R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
    Hibberd PL; Davidson L
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S137-40; discussion S144-51. PubMed ID: 18181720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Business considerations in the development of probiotics.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S141-3; discussion S144-51. PubMed ID: 18181721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns.
    Freedman SB; Schnadower D; Tarr PI
    JAMA; 2020 Mar; 323(9):823-824. PubMed ID: 32125410
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical research on probiotics: the interface between science and regulation.
    Tamayo C
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S101-3; discussion S144-51. PubMed ID: 18181711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current marketplace for probiotics: a Japanese perspective.
    Amagase H
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S73-5; discussion S144-51. PubMed ID: 18181727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics in the United States.
    Vanderhoof JA; Young R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S67-72; discussion S144-51. PubMed ID: 18181726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental assessment requirements for live biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergen-free probiotics.
    Mogna G; Strozzi GP; Mogna L
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S201-4. PubMed ID: 18685500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing probiotic research in humans in the United States: Challenges and strategies.
    Sanders ME; Shane AL; Merenstein DJ
    Gut Microbes; 2016; 7(2):97-100. PubMed ID: 26963522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of guidelines in the development and application of probiotics.
    Reid G;
    Curr Pharm Des; 2005; 11(1):11-6. PubMed ID: 15638748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics: definition, sources, selection, and uses.
    Sanders ME
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S58-61; discussion S144-51. PubMed ID: 18181724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotics--the friendly bacteria with market potential in global market.
    Khan SH; Ansari FA
    Pak J Pharm Sci; 2007 Jan; 20(1):76-82. PubMed ID: 17337434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 18. Health-benefit claims for probiotic products.
    Heimbach JT
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S122-4; discussion S144-51. PubMed ID: 18181716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe and efficacious probiotics: what are they?
    Reid G
    Trends Microbiol; 2006 Aug; 14(8):348-52. PubMed ID: 16809039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulating the safety of probiotics--the European approach.
    von Wright A
    Curr Pharm Des; 2005; 11(1):17-23. PubMed ID: 15638749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.